About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Synthetic Carrier Developed by Mayo Clinic can Deliver Drugs Through Blood-Brain Barrier

by Kathy Jones on June 6, 2014 at 7:16 PM
 Synthetic Carrier Developed by Mayo Clinic can Deliver Drugs Through Blood-Brain Barrier

A synthetic peptide carrier developed by Mayo Clinic researchers was able to transfer drugs through the blood-brain barrier, emerging as a potential vehicle for delivering brain cancer chemotherapy drugs and other neurological medications to the brain, a new study published in the journal PLOS ONE reveals.

"Not only have we shown that we can transport eight different molecules, we think this method will be less disruptive or invasive because it mimics a normal physiological process," says Mayo Clinic neuroscientist Gobinda Sarkar, Ph.D., the corresponding author of the study. The researchers are able to transport the drugs without modifying any of the molecules involved. They say this development will aid in evaluation of potential new drugs for brain cancer.

Advertisement

The blood-brain barrier is meant to protect the brain from numerous undesirable chemicals circulating in the body, but it also obstructs access for treatment of brain tumors and other conditions. Too often the only recourse is invasive, which often limits a drug's effectiveness or causes irreversible damage to an already damaged brain. Nearly all of the drugs that could potentially help are too large to normally pass through the barrier. Additionally, other methods may damage the vascular system.

In this case, the synthetic peptide K16ApoE, once injected into a vein, binds to proteins in the blood to create entities that can pass for near-normal ligands to some receptors present on the blood-brain barrier. The 'pseudo-ligand' receptor interaction creates what the researchers believe to be transient pores through which various molecules can be transported to the brain. The molecules they've transported in this manner include cisplatin, methotrexate, cetuximab, three different dyes, and synthetic peptides Y8 and I-125. The researchers believe this is the least complicated, least expensive and most versatile method for delivering therapeutics to the brain. Previously, the researchers delivered antibodies targeted against amyloid plaques into the brains of mouse models of Alzheimer's disease using this same method.
Advertisement

"We know that some chemotherapeutic agents can kill brain tumor cells when they are outside the brain (as in a laboratory test). But because the agents cannot cross the blood-brain barrier, they are not able to kill brain tumor cells inside the brain. With the peptide carrier, these agents can now get into the brain and potentially kill the tumor cells," says Mayo neurology researcher Robert Jenkins, M.D., Ph.D., senior author of the study.

The researchers say their method, which has been successfully demonstrated in mice, meets three of five requirements for a usable therapy: It's feasible as a repeated procedure; it should be relatively easy to introduce into medical practice; and it would work for any size or location of brain tumor. More research will need to be done to prove effectiveness and determine any adverse effects.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Synthetic Carrier Developed by Mayo Clinic can Deliver Drugs Through Blood-Brain Barrier Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests